RPS6KB1 and neoplasm: The tumor growth inhibition of NVP-BEZ235 targeting NPC xenografts was dose-dependent, and the observed effect of the phosphorylation of AKT, GSK3β, S6K and 4E-BP1 correlated with the amount of compound presented in the tumor tissue.